EDG-7500 for Liver Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Are You a Good Fit for This Trial?
Adults over 18 with varying levels of liver function, including those with mild to moderate hepatic impairment, can join this trial. Participants must be non-smokers or moderate smokers, have a BMI between 18 and 40 kg/m2, and normal kidney function. They should also agree to follow contraception guidelines.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of EDG-7500
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- EDG-7500
Trial Overview
The study is testing EDG-7500 in adults to see how different levels of liver health affect the drug's presence in the blood after one dose. It will compare results from those with normal liver function to those with impaired liver function.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Edgewise Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.